行情

OCUL

OCUL

Ocular
NASDAQ

实时行情|Nasdaq Last Sale

2.800
+0.060
+2.19%
已收盘, 16:00 11/19 EST
开盘
2.710
昨收
2.740
最高
2.930
最低
2.710
成交量
48.78万
成交额
--
52周最高
6.88
52周最低
2.350
市值
1.35亿
市盈率(TTM)
-1.5571
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OCUL 新闻

  • 拼多多三季度营收低于市场预期 盘前大跌13%
  • 新浪科技.25分钟前
  • 定价176港元,阿里巴巴首日盈利空间还有多大?
  • 华盛通.29分钟前
  • 阿里巴巴融资880亿港元 为2010年以来香港最大IPO
  • 新浪财经.39分钟前
  • 拼多多Q3财报:营收增长123%至75.139亿元
  • 新浪财经.45分钟前

更多

所属板块

医疗设备、用品及经销
+0.71%
医疗设备和用品
+1.01%

热门股票

名称
价格
涨跌幅

OCUL 简况

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
展开

Webull提供Ocular Therapeutix Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。